TP53 and pancreatic adenocarcinoma: Previous research has shown a large proportion of TP53 mutations (64%-83%) in PAAD cases (19), which is consistent with our findings, thus suggesting the potential of MVP as a promising biomarker in clinical diagnosis of PAAD.